The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab

Acta Oncologica

Volumn 53, Issue 9, 2014, Pages 1212-1220

  Berglund, Åke ^a   Willén, Linda ^b   Grödeberg, Lina ^b   Skattum, Lillemor ^c   Hagberg, Hans ^a   Pauksens, Karlis ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GÄVLE HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIEMETIC AGENT; CORTICOSTEROID; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; PNEUMOCOCCUS VACCINE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN G; INACTIVATED VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; NEOPLASM; OUTPATIENT; SEASONAL INFLUENZA; SEROCONVERSION; SEROTYPE; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT RESPONSE; VIRION; VIRUS STRAIN; AMBULATORY CARE; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; NEOPLASMS; PNEUMOCOCCAL INFECTIONS; PROSPECTIVE STUDY; SWEDEN; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEOPLASMS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; SWEDEN; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84907226777     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.914243     Document Type: Article

References (34)

1. Brydak LB, Marchala M. Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 2000;60:35-53.
2. Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977;39:350-3.
3. Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppres- sive chemotherapy. J Oncol Pharm Pract 2006;12:143-54.
4. Kempe A, Hall CB, MacDonald NE, Foye HR, Woodin KA, Cohen HJ, et al. Influenza in children with cancer. J Pediatr 1989;115:33-9.
5. Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis 1997;24:1095-9.
6. Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL 3rd, Lee JY. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552-7.
7. Morens DM, Taubenberger JK, Fauci AS. The persistent legacy of the 1918 influenza virus. N Engl J Med 2009; 361:225-9.
8. Prato R, Tafuri S, Fortunato F, Martinelli D. Why is it still important that countries know the burden of pneumococcal disease. Hum Vaccin 2010;6:918-21.
9. Recommendations of the Swedish National Board of Health andWelfare: Influenza vaccination. (Socialstyrelsens allmanna rad. Vaccination mot influenza. SOFS 1997:21. [cited 2012 Oct 25]. Available from: http://www.socialstyrelsen.se/sosfs/1997-21.
10. Hehme NW, Kunzel W, Petschke F, Turk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix. Clin Drug Invest 2002;22: 751-69.
11. World Health Organization: The immunological basis for immunization series. Immunological basis for immunization: Pneumococcal vaccine. 2009. WHO/IVB/ISBN978924 1598217.
12. Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol 2010;134:198-205.
13. Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 2001;19:1671-7.
14. Shildt RA, Rubin RR, Schiffman G, Giolma P. Polyvalent pneumococcal immunization of patients with plasma cell dyscrasias. Cancer 1981;48:1377-80.
15. Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordey T, et al. Rituximab blocks protective serologic response to influenza A(H1N1) 2009 vaccination in lym-phoma patients during or within 6 months after treatment. Blood 2011;118:6769-71.
16. Mackay HJ, McGee J, Villa D, Gubbay JB, Tinker LM, Shi L. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and haematological malignancies on active systemic treatment. J Clin Virol 2011;50:212-6.
17. Nordey T, Aaberge IS, Husebekk A Samdal HH, Steinert S, Melby H, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19:71-8.
18. Meerveld-Eggink A, de Weerdt O, van der Velden AM, Los M, van der Velden AW, Stouthard JM. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011;22:2031-5.
19. Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011;186:644-55.
20. Rousseau B, Loulergue P, Mir O, Krivine A, Kotti S, Viel E. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: The VACANCE study. Ann Oncol 2012;23:450-7.
21. Loulergue P, Alexandre J, Iurisci I, Grabar S, Medioni J, Ropert S. Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: Results of a prospective pilot study. Br J Cancer 2011;104:1670-4.
22. Hottinger AF, George AC, Bel M, Favet L, Combescure C, Meier S, et al. A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist 2012;17: 436-45.
23. Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, Xiao YY, et al. Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist 2012;17:125-34.
24. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740-5.
25. Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: Systematic review and meta-analysis. Influenza Other Respir Viruses 2011;5:299-305.
26. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-60.
27. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: A randomised study. Br J Haematol 2005;130:96-8.
28. Vila-Corcoles A, Ochoa-Gondar O, Guzman JA, Rodriques-Blanco T, Salsench E, Fuentes CM, et al. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infec Dis 2010;10:73.
29. Edwards JC, Szcezepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
30. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards J C. Reconstitution of peripheral blood B-cells after depletion with rituximab in patient with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
31. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010; 120:76-85.
32. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: A review of infection, frequency, morbidity, mortality and vaccine responses. Lancet Infect Dis 2009;9: 493-504.
33. Pauksens K. Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine. Infect Ecol Epidemiol 2013;3.
34. Loulergue P, Mir O, Alexandre J, Ropert S, Goldwasser F, Launay O. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008;19: 1658.